Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (2) · (multiple, generic dominant) (1) · Ventolin, ProAir, Proventil, AccuNeb (1)

Analgesic (2) · GABAergic (1) · Opioid (2) · Prodrug (1) · Research material (1) · [[:Category:Beta-2_adrenergic_agonists|Short-acting β2-agonist]] (1) · [[:Category:Bronchodilators|Bronchodilator]] (1)

Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Prodrug of GHB (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · '"`UNIQ--vote-00000093-QINU`"' At higher doses β2 selectivity is lost, producing β1 effects (tachycardia, tremor) and hypokalemia from intracellular potassium shift'"`UNIQ--ref-00000094-QINU`"'. (1)

None (2) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000095-QINU`"', '"`UNIQ--vote-00000096-QINU`"', '"`UNIQ--vote-00000097-QINU`"', '"`UNIQ--vote-00000098-QINU`"' (1)

None (2) · Adult: 15–60 mg every 4 hours as needed. (1) · MDI 90 mcg/puff, 2 puffs q4-6h prn; nebulized 2.5 mg in 3 mL saline q4-6h (1)

None (2) · MDI 90 mcg/puff; nebulizer solution 0.083% (2.5 mg/3 mL), 0.5%, 0.021%, 0.042%; syrup 2 mg/5 mL; 2 mg, 4 mg tablets; 4 mg, 8 mg ER (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (2) · 12 inhalations/d (rescue); higher for severe exacerbation under monitoring (1) · 360 mg/day (1)

None (2) · Inhaled (MDI (1) · nebulized) (1) · Oral (1) · PO (only formulation marketed in the US). (1)

None (2) · 30–60 min (PO) (1) · Inhaled: 5-15 minutes; PO: 30 minutes (1)

None (2) · 4-6 hours (1) · 4–6 hours (1)

None (2) · 2.5–3 hours (1) · 4-6 hours (inhaled and PO)'"`UNIQ--ref-00000099-QINU`"' (1)

None (2) · ~10% inhaled reaches systemic circulation; ~50% PO'"`UNIQ--ref-0000009A-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (2) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Preferred SABA in pregnancy; benefits of asthma control outweigh limited risks.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (2) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (1)